Publications by authors named "Cynthia B Leary"

Claim this Profile
D
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, Cynthia B Leary, Molly M Hood

Bioorg Med Chem Lett· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Bryan D Smith, Michael D Kaufman, Scott C Wise, Yu Mi Ahn, Timothy M Caldwell, Cynthia B Leary

Mol Cancer Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary

Cancer Cell· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.
Allison S Harney, George S Karagiannis, Jeanine Pignatelli, Bryan D Smith, Ece Kadioglu, Cynthia B Leary

Mol Cancer Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Bryan D Smith, Michael D Kaufman, Cynthia B Leary, Benjamin A Turner, Scott C Wise

Mol Cancer Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis